Castle Biosciences, Inc.
CSTL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $740,230 | $578,387 | $613,311 | $1,077,623 |
| - Cash | $119,709 | $98,841 | $122,948 | $329,633 |
| + Debt | $26,344 | $15,335 | $13,310 | $8,079 |
| Enterprise Value | $646,865 | $494,881 | $503,673 | $756,069 |
| Revenue | $332,069 | $219,788 | $137,039 | $94,085 |
| % Growth | 51.1% | 60.4% | 45.7% | – |
| Gross Profit | $271,864 | $174,806 | $105,030 | $78,263 |
| % Margin | 81.9% | 79.5% | 76.6% | 83.2% |
| EBITDA | $38,138 | -$45,024 | -$58,344 | -$36,604 |
| % Margin | 11.5% | -20.5% | -42.6% | -38.9% |
| Net Income | $18,245 | -$57,466 | -$67,138 | -$31,292 |
| % Margin | 5.5% | -26.1% | -49% | -33.3% |
| EPS Diluted | 0.62 | -2.14 | -2.58 | -1.24 |
| % Growth | 129% | 17.1% | -108.1% | – |
| Operating Cash Flow | $64,866 | -$5,626 | -$41,655 | -$18,983 |
| Capital Expenditures | -$28,326 | -$13,621 | -$5,632 | -$3,483 |
| Free Cash Flow | $36,540 | -$19,247 | -$47,287 | -$22,466 |